BNET Industries
Last Fiscal Year Sales:$35.9B
- Public
- DE
Dow Jones Description
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and improved earning power. We already successfully reorganized the Bayer Group and further streamlined our portfolio to create a new Bayer that is focused on its corporate strengths, its customers and the markets of the future. To help us achieve this goal, we then carried out a strategic realignment in order to concentrate in future on three high-potential, agile subgroups with largely independent operations: HealthCare, CropScience and MaterialScience, supported by three service companies. Our operating companies give us the access we need to the growth markets of the future. As an inventor company, we plan to continue setting trends in research-intensive areas. Innovations are the foundation for our competitiveness and our corporate growth, and thus for our success in the future. We believe our technical and commercial expertise entails a duty to contribute to sustainable development ? a principle we wholeheartedly endorse, mindful of its social, ethical and environmental elements. In awareness of our responsibilities as a corporate citizen, we define economy, ecology and social commitment as objectives of equal rank. We seek to retain society?s confidence through performance, flexibility and open communication as we work in pursuit of our overriding corporate goals: to steadily create corporate value and generate high value-added for the benefit of our stockholders, our employees and the community in every country in which we operate.
Director, Finance
Klaus KuhnNumber of Employees 122,100
Peer Companies
NAICS Code Plastics Material and Resin Manufacturing: 325211
Recent Events
-
Bayers Betaferon approved in China for Treatment of Multiple Sclerosis
-
UPDATE 3-US FDA declines to approve Endo testosterone drug
-
UPDATE 1-Futuragene signs licence deal with Bayer CropScience
-
Bayer and United Nations Environment Programme Launch 19th Annual International Children's...
-
Bayer Consumer Care Launches CitracalR Calcium Plus Heart Health
-
German drug, chemical company Bayer's Q3 net income falls 10 per cent
-
Bayer, US Onyx launch phase III trial of Nexavar in patients with non-responsive thyroid cancer
-
BRIEF-Credit Suisse raises targets on European pharma cos
-
Bayer accused of hiding Yaz contraceptive risk
-
Bayer downgraded to neutral from buy at UBS
-
Abbott Laboratories to acquire Solvay Pharmaceuticals
-
Bayer's contested kidney cancer drug shows benefit
-
Bayer names new CEO
-
Bayer Introduces CONTOUR USB - The First Blood Glucose Meter With Unique Plug & Play...
-
Bayer's next CEO has a year to prepare Today
News & Analysis
Filter by
bayer ag and health care - All News and Analysis
Healthcare Roundup: Reform "Integral" to Recovery, Bayer's $98M Payment, Hospital Inflation Down, and More
Healthcare reform is "integral" to economic recovery, Obama says; Bayer HealthCare pays a $98M settlement; hospital inflation is down slightly, but still high; and more. by David P. Hamilton
Bayer Animal Health Introduces Credo™ SC Insecticide
A New Addition to Your Darkling Beetle Arsenal
ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare
NGN Capital leads $12 Million in Series A First Tranche Financing
Regeneron and Bayer HealthCare Announce Encouraging 32-Week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-Related Macular Degeneration
Gains in visual acuity achieved in initial 12-week fixed dosing phase of study maintained in PRN (as-needed) dosing phase
Research and Markets: Bayer Healthcare Analysed in New Strategic Analysis Profile
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c88265) has announced the addition of Bayer Healthcare Strategic Analysis Profile to their offering.
Educational Children's Book About Hemophilia Now Available from Bayer HealthCare and BioRx
CINCINNATI -- Bayer HealthCare and BioRx, a specialty pharmaceutical company, announce the availability of I AM NATE, a new children's book about hemophilia. Written by Chris Perretti Barnes, the mother of a young boy with hemophilia A, the book is the second in a series of books intended to educate...
Bayer Healthcare Pharmaceuticals Streamlines Workplace Processes with FM:Systems Facility Management Software
FM:Systems' Flagship Product, FM:Interact, Provides Bayer with Real-Time Access to Accurate Space, Occupancy and Asset Information
Regeneron and Bayer HealthCare Initiate Phase 3 Global Development Program For VEGF Trap-Eye In Wet Age-Related Macular Degeneration
Study will compare the VEGF Trap-Eye to ranibizumab (Lucentis([R]))
Proteros biostructures Announce Successful Achievement of Milestone in Fragment-Based Protein Crystallography Collaboration
MARTINSRIED, Germany -- Proteros biostructures GmbH announced today that the first milestone of their research collaboration with Bayer HealthCare in the field of fragment-based protein crystallography has been successfully achieved, triggering the associate milestone payment. In the collaboration, which started in June 2006, Proteros applies its target know-how, industrial process...
It's Time to Start Checking for Ticks: Bayer Animal Health Offers Tips to Protect Humans and Dogs from Discomfort and Disease
SHAWNEE, Kan. -- Bayer Animal Health is reminding pet owners that now is the time to consider their options for protecting both themselves and their pets from the discomfort and disease that can be caused by fleas, ticks, and mosquitoes.
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Klaus Kuhn | Director, Finance |
| Richard Pott | Director, Strategy and Human Resources |
| Wolfgang Plischke | Director, Innovation, Technology and Environment |
| Hartmut Klusik | Head, Product Supply |
| Gary S Balkema | Executive Committee Member |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Arthur J Higgins | Chairman, HealthCare |
| Werner Wenning | Executive Chairman |
| Klaus Kleinfeld | Board of Directors |
| Paul Achleitner | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Director, Finance | Current |
| University of South Carolina | MBA | Former |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Director, Strategy and Human Resources | Current |
| University of Cologne | doctorate in physics | Former |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Director, Innovation, Technology and Environment | Current |
| Bayer HealthCare AG | Manager | Current |
| Bayer HealthCare AG | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Head, Product Supply | Current |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Chairman, HealthCare | Current |
| Enzon Pharmaceuticals, Inc. | CEO | Former |
| Pharmaceutical Research and Manufacturers of America | member | Former |
| Bayer HealthCare, Animal Health Division | Chairman | Former |
| Enzon Pharmaceuticals, Inc. | Chairman | Former |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Executive Chairman | Current |
| Henkel AG & Co. KGaA | Supervisory Board | Current |
Klaus Kleinfeld is president and chief executive officer of Alcoa. He joined the company in 2007 as president and chief operating officer and seven months later assumed CEO responsibilities. He has served on Alcoa's board of directors since 2003. Alcoa is a world leader in the production and management of a very sustainable product: aluminum. Nearly 75% of the aluminum ever produced since 1888 is still in use today. The company has been a technology leader since its beginning, providing more than 90% of the aluminum alloys used in aircraft and space flight; helping making automobiles lighter, without compromising safety or performance; manufacturing sheet that created the ultimate recyclable container, the aluminum beverage can; and providing building and construction industry materials that help further the green building movement. In addition, to serving customers in these markets, Alcoa also markets wheels, fastening systems, precision and investment castings, and building systems. The company has 97,000 employees in 34 countries. Before coming to Alcoa, Mr. Kleinfeld had a 20-year career with Siemens, the global electronics and industrial conglomerate, based in the U.S. and Germany, where he served as chief executive officer of Siemens AG starting in 2005. During his tenure, Mr. Kleinfeld presided over a dramatic transformation of the company, reshaping the company's portfolio around three high growth areas, resulting in increase of revenues and market capitalization nearly doubled. Prior to his service on the Managing Board of Siemens AG, Mr. Kleinfeld was President and Chief Executive Officer of Siemens Corporation, its U.S. arm and the company's largest region. In addition to serving on Alcoa's board, he is a member of the board of Bayer AG. On the personal front, Mr. Kleinfeld was born in Bremen, Germany and educated at the University of Goettingen and University of Wuerzburg, both in Germany. He holds a Ph.D in strategic management and master's degree in business administration. In his leisure time, he enjoys skiing, tennis, the arts and is a marathon runner. Mr. Kleinfeld resides in New York with his wife and children.
| Organization | Position | Status |
|---|---|---|
| Alcoa, Inc. | President & Chief Executive Officer | Current |
| Bayer AG | Board of Directors | Current |
| Alcoa, Inc. | Board of Directors | Current |
| Siemens AG | President & CEO | Former |
| Siemens Corporation | Chief Executive Officer | Former |
| Alcoa, Inc. | Chief Operating Officer | Former |
| Siemens Corporation | Chief Operating Officer | Former |
| Siemens AG | Chief Operations Officer, U.S. | Former |
| Siemens AG | Executive Vice President | Former |
| Siemens AG | Audit Committee Principal | Former |
| Citigroup Inc. | Board of Directors | Former |
| Siemens AG | Board of Directors | Former |
| Siemens Corporation | member | Former |
| Organization | Position | Status |
|---|---|---|
| Allianz SE | Executive Director, Finance | Current |
| Bayer AG | Board of Directors | Current |
| Goldman, Sachs & Co. | Vice President, Mergers & Acquisitions | Former |
| Bain & Company | Manager, Strategy Consulting | Former |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Executive Committee Member | Current |
| Bayer HealthCare, Animal Health Division | President, Worldwide Bayer Consumer Care Division | Former |
| Fairleigh Dickinson University | master of business administration degree | Former |
Executive News
-
Report from Europe: U.S. Close vs. China Rebound
-
Alcoa Named Component of Dow Jones Sustainability Index for Eighth Consecutive Year
-
Alcoa says global aluminium demand to fall 5.5 pct -Bloomberg
-
Siemens To Settle Bribery Charges with Three Former Execs
-
Siemens poised to settle with ex-managers
-
UPDATE 1-Siemens poised to settle with ex-managers
-
UPDATE 1-Siemens poised to settle with ex-managers
-
Bayer AG (BAY.F) May Be Ready for Deals After Lost Intervet Bid
-
Inventories May Temper Aluminum Rally
Industry Transcripts by Seeking Alpha
-
Deere & Company F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Nov 25, 2009about DE
-
Brown Shoe Co. Inc. Q3 2009 Earnings Call Transcript
on Nov 24, 2009about BWS
-
Daktronics Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Nov 24, 2009about DAKT
-
Haynes International Inc. F4Q09 (Qtr End 09/30/09) Earnings Call Transcript
on Nov 24, 2009about HAYN
-
Valspar Corp. F4Q09 (Qtr End 30/10/09) Earnings Call Transcript
on Nov 23, 2009about VAL
